Busulfan (BU)

DRUG15 trials

Sponsors

Nanfang Hospital, Southern Medical University, Masonic Cancer Center, University of Minnesota

Conditions

Acute Lymphocytic LeukemiaAcute Myeloid LeukemiaAllogeneic Hematopoietic Stem Cell TransplantationAutologous Hematopoietic Stem Cell TransplantationBiphenotypic/Undifferentiated LeukemiaBurkitt LymphomaBusulfanChronic Myelogenous Leukemia

Phase 2

IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT

CompletedNCT02671708

Nanfang Hospital, Southern Medical UniversityAcute Myeloid Leukemia, Autologous Hematopoietic Stem Cell Transplantation, Conditioning

Start: 2016-01-31End: 2020-02-28Updated: 2020-03-03

G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

CompletedNCT02744742

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myelodysplastic Syndrome

Start: 2016-04-18End: 2021-09-30Updated: 2022-02-14

BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT

Nanfang Hospital, Southern Medical UniversityAutologous Hematopoietic Stem Cell Transplantation, Conditioning, Diffuse Large B-cell Lymphoma

Start: 2017-07-05End: 2020-06-30Target: 122Updated: 2017-10-12

Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT

Nanfang Hospital, Southern Medical UniversityAutologous Hematopoietic Stem Cell Transplantation, Conditioning, Multiple Myeloma

Start: 2018-01-02End: 2021-12-31Target: 122Updated: 2020-02-25

Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAcute Myeloid Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning +1

Start: 2018-06-15End: 2022-04-01Target: 60Updated: 2020-12-22

Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditions, Mixed-lineage-leukemia (MLL)-Rearranged Acute Leukemia

Start: 2018-07-31End: 2022-06-30Target: 122Updated: 2018-07-24

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Active, not recruitingNCT03674411

Masonic Cancer Center, University of MinnesotaAcute Lymphocytic Leukemia, Acute Myeloid Leukemia, Biphenotypic/Undifferentiated Leukemia +8

Start: 2019-01-02End: 2026-12-01Updated: 2026-01-06

BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT

Nanfang Hospital, Southern Medical UniversityAutologous Hematopoietic Stem Cell Transplantation, Conditioning, Primary Central Nervous System Lymphoma

Start: 2018-11-30End: 2021-10-31Target: 20Updated: 2018-11-07

Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myeloid Tumors

Start: 2019-09-30End: 2023-08-31Target: 196Updated: 2019-09-23

Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myeloid Tumors +1

Start: 2019-10-31End: 2023-09-30Target: 196Updated: 2019-10-10

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myelodysplastic Syndrome

Start: 2021-01-15End: 2024-07-31Target: 242Updated: 2021-01-19

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Secondary Acute Myeloid Leukemia Evolving From MDS

Start: 2022-07-31End: 2024-12-31Target: 232Updated: 2022-07-08

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myelodysplastic Syndrome

Start: 2022-07-01End: 2024-12-31Target: 242Updated: 2023-03-21

VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

Not yet recruitingNCT07052422

Nanfang Hospital, Southern Medical UniversityConditioning, Hematopoietic Stem Cell Transplantation (HSCT), Myeloid Malignancies +1

Start: 2025-07-15End: 2029-12-31Target: 160Updated: 2025-07-04

Phase 3

BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT

CompletedNCT02670252

Nanfang Hospital, Southern Medical UniversityAcute Lymphocytic Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan +1

Start: 2016-01-31End: 2022-02-28Updated: 2022-04-08

Related Papers

Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trial.

2025-08-121 citations

The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial.

2023-01-2319 citations

Idarubicin plus <scp>BuCy</scp> versus <scp>BuCy</scp> conditioning regimens for intermediate‐risk acute myeloid leukemia in first complete remission undergoing <scp>auto‐HSCT</scp>: An open‐label, multicenter, randomized phase 3 trial

American Journal of Hematology2023-01-015 citations

Effect of Two Conditionings on Relapse in Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

Blood2022-11-15

Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial

Journal of Clinical Oncology2022-09-0948 citations

Mgta-456, a Cell Therapy Utilizing Expansion of CD34+ Hematopoietic Stem Cells (HSC), Improves HLA Matching for Adult Recipients, Promotes Faster Hematopoietic Recovery and Enables Uniform Engraftment with Less Acute Graft-Vs-Host Disease (GVHD)

Biology of Blood and Marrow Transplantation2020-01-23

Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD)

Blood2019-11-134 citations